Pharmacogenetics of antidepressive treatment

@article{Zobel2009PharmacogeneticsOA,
  title={Pharmacogenetics of antidepressive treatment},
  author={Astrid W. Zobel and Wolfgang Maier},
  journal={European Archives of Psychiatry and Clinical Neuroscience},
  year={2009},
  volume={260},
  pages={407-417}
}
  • A. Zobel, W. Maier
  • Published 3 January 2010
  • Biology, Psychology, Medicine
  • European Archives of Psychiatry and Clinical Neuroscience
The search of the genetic predictors of response to antidepressants is a rapidly expanding field. A large number of clinical studies are reporting partly inconsistent results. Emerging new results focus on new candidate single nucleotide polymorphisms—particularly in the 5HT2a-receptor gene and the gene coding for the co-chaperone FKBP5. The impact of the 5HTTLPR polymorphism on therapeutic outcome and side effects under treatment with SSRIs has to be viewed in a more complex manner than… 

Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D

This study demonstrates the potential of GWAS to discover genes and pathways that could mediate adverse effects of antidepressant medication, and indicates that 10 SNPs in SACM1L mediated the effects of bupropion on sexual side-effects.

Pharmacogenetics and analgesic effects of antidepressants in chronic pain management.

The current knowledge of the influence of genetic factors on the plasma concentrations, efficacy and adverse effects of the major antidepressants used in pain management is discussed.

Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D

This study demonstrates the potential of genome-wide association studies to discover genes and pathways that potentially mediate adverse effects of antidepressant medications and identifies genetic variation influencing susceptibility to citalopram-induced side effects.

Pharmacogenomics and Personalized Medicine in Mood Disorders

Pharmacogenomics and the search for personalized medicine focus on the attainment of individualized pharmacotherapies that cover genetic variation and target groups of patients that present

CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.

Genetic variants in the CYP1A2 region may be indicators of treatment response in MDD patients to paroxetine.

Fluoxetine pharmacogenetics in child and adult populations

It is concluded that the different polymorphisms of CYP2D6 and CYP1C9 may influence the blood concentrations of fluoxetine, and if the childhood dose is adjusted for weight, differences between children and adults are unlikely.

Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance

The protein processing in endoplasmic reticulum pathway (hsa04141) was the best pathway that may explain the mechanisms of MAPK1 involvement in antidepressant response.

DNA sequence variants of the FKBP5 gene are associated with unipolar depression.

This study extends the replicated association of a promoter SNP with antidepressant response on a biological level by demonstrating normalization of the cortisol response under Dex/CRH stimulation during treatment.

Interaction of SLC1A1 gene variants and life stress on pharmacological resistance in obsessive–compulsive disorder

A gene-by-environment interaction effect on treatment resistance in OCD is suggested and the existing evidence of the role of the glutamatergic system in the phenomenology of OCD is strengthened.

References

SHOWING 1-10 OF 63 REFERENCES

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.

There is a compelling case for a key role of HTR2A in the mechanism of antidepressant action, as detected in patients treated with the antidepressant citalopram.

Genetic variants in FKBP5 affecting response to antidepressant drug treatment.

An effect of FKBP5 variants on antidepressant drug response was confirmed in an independent cohort of depressed patients; however, with an odds ratio of 1.8 the effect size was smaller than that described earlier.

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

Combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions.

Genetic predictors of response to antidepressants in the GENDEP project

The pattern of associations indicated a degree of specificity with variants in genes encoding proteins in serotonin signaling influencing response to the serotonin-reuptake-inhibiting escitalopram, genes encode proteins in norepinephrine signaling influencingresponse to the norpinephrine-reptake- inhibiting nortriptyline and a common pathway gene influencing response in response to both antidepressants.

Antidepressant Drug Discovery in the Postgenomic Era

  • F. Holsboer
  • Psychology, Biology
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2001
To achieve the goal of genotype/phenotype-based differential therapy, large-scale efforts with regards to both patient samples and genotyping capacities are needed, and increasingly detailed patient information, if translated into specific pharmacological treatments, will lead to customized drugs and thus to a partial fragmentation of the antidepressant market.

Investigation of serotonin-related genes in antidepressant response

Results implicate TPH1 and SLC6A4 in general response, and HTR2A, TPH2, and MAOA in the specificity of response to fluoxetine, and a number of the less frequent alleles of many of the SNP markers were associated with the nonresponse and nonspecific phenotypes.

Association of the COMT val158met Variant with Antidepressant Treatment Response in Major Depression

The present results strongly point toward a negative influence of the higher activity COMT 158val/val genotype on antidepressant treatment response during the first 6 weeks of pharmacological treatment in major depression, possibly conferred by consecutively decreased dopamine availability.

Sequence Analysis of the Serotonin Transporter and Associations with Antidepressant Response

...